TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

EMERPHED

EPHEDRINE SULFATE
Approved 2020-04-17
1
Indication
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2020-04-17
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: EPHEDRINE SULFATE

EMERPHED Approval History

Loading approval history...

What EMERPHED Treats

1 indications

EMERPHED is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypotension
Source: FDA Label

Drugs Similar to EMERPHED

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EMERPHED FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

EMERPHED is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. EMERPHED is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

EMERPHED Patents & Exclusivity

Latest Patent: May 2040

Patents (14 active)

US11478436 Expires May 16, 2040
US11090278 Expires May 16, 2040
US11571398 Expires May 16, 2040
US11241400 Expires May 16, 2040
US11464752 Expires May 16, 2040
+ 4 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.